Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O75443
UPID:
TECTA_HUMAN
Alternative names:
-
Alternative UPACC:
O75443
Background:
Alpha-tectorin plays a pivotal role in hearing by being a major non-collagenous component of the tectorial membrane in the inner ear. This membrane is crucial for sound transduction, interacting directly with sensory hair cells to convert sound waves into electrical signals.
Therapeutic significance:
Given its critical function in hearing, mutations in Alpha-tectorin are linked to autosomal dominant and recessive forms of non-syndromic sensorineural hearing loss. Understanding the role of Alpha-tectorin could open doors to potential therapeutic strategies for these hearing impairments.